{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:34:27Z","timestamp":1771850067920,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1124\/jpet.124.002347","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:00:12Z","timestamp":1730739612000},"page":"100047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia"],"prefix":"10.1016","volume":"392","author":[{"given":"Sean M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Toolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Kandebo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Vardigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izzat","family":"Raheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Gantert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Riffel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hostetler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Uslaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.124.002347_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuropharm.2012.05.003","article-title":"The nicotinic \u03b17 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys","volume":"64","author":"Cannon","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1124\/jpet.124.002347_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/jpet.111.182766","article-title":"Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker","volume":"339","author":"Dedeurwaerdere","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002347_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuropharm.2017.01.016","article-title":"In\u00a0vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects","volume":"117","author":"Delnomdedieu","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.124.002347_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0000000000001047","article-title":"A\u00a0proof-of-concept study evaluating the phosphodiesterase 10A inhibitor PF-02545920 in the adjunctive treatment of suboptimally controlled symptoms of schizophrenia","volume":"39","author":"DeMartinis","year":"2019","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1124\/jpet.124.002347_bib7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1037\/0735-7044.103.3.526","article-title":"Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants","volume":"103","author":"Diamond","year":"1989","journal-title":"Behav Neurosci"},{"key":"10.1124\/jpet.124.002347_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00213-013-3260-0","article-title":"The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey","volume":"231","author":"Eddins","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.124.002347_bib9","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1124\/jpet.124.002347_bib10","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.107.043786","article-title":"Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs","volume":"73","author":"Fumagalli","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.124.002347_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuropharm.2015.05.024","article-title":"The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents","volume":"99","author":"Gentzel","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu Rev Neurosci"},{"key":"10.1124\/jpet.124.002347_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40268-017-0214-8","article-title":"A\u00a0randomized multiple dose pharmacokinetic study of a novel PDE10A inhibitor TAK-063 in subjects with stable schizophrenia and Japanese subjects and modeling of exposure relationships to adverse events","volume":"17","author":"Goldsmith","year":"2017","journal-title":"Drugs R D"},{"key":"10.1124\/jpet.124.002347_bib14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002347_bib15","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00213-013-3371-7","article-title":"Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating","volume":"231","author":"Gresack","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.124.002347_bib16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.15252\/emmm.201506085","article-title":"A\u00a0novel thermoregulatory role for PDE10A in mouse and human adipocytes","volume":"8","author":"Hankir","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1124\/jpet.124.002347_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s11307-015-0910-0","article-title":"Preclinical characterization of the phosphodiesterase 10A PET tracer [(11)C]MK-8193","volume":"18","author":"Hostetler","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1124\/jpet.124.002347_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"key":"10.1124\/jpet.124.002347_bib19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0306-4522(98)00481-3","article-title":"Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits","volume":"90","author":"Jentsch","year":"1999","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.124.002347_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies","volume":"4","author":"Lammertsma","year":"1996","journal-title":"Neuroimage"},{"key":"10.1124\/jpet.124.002347_bib23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.115.226712","article-title":"The M1 muscarinic positive allosteric modulator PQCA improves performance on translatable tests of memory and attention in rhesus monkeys","volume":"355","author":"Lange","year":"2015","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002347_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108754","article-title":"Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer\u2019s disease and schizophrenia in rhesus monkey","volume":"197","author":"Lange","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib25","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1021\/acs.jmedchem.2c01521","article-title":"Discovery of MK-8189, a highly potent and selective PDE10A inhibitor for the treatment of schizophrenia","volume":"66","author":"Layton","year":"2023","journal-title":"J\u00a0Med Chem"},{"key":"10.1124\/jpet.124.002347_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.schres.2018.08.028","article-title":"A\u00a0phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia","volume":"204","author":"Macek","year":"2019","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.124.002347_bib27","first-page":"54","article-title":"Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia","volume":"8","author":"Menniti","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.124.002347_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.600178","article-title":"PDE10A inhibitors-clinical failure or window into antipsychotic drug action?","volume":"14","author":"Menniti","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.124.002347_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2024.05.019","article-title":"Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: a randomized proof-of-concept clinical trial","volume":"270","author":"Mukai","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.124.002347_bib30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/db13-0247","article-title":"Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance","volume":"63","author":"Nawrocki","year":"2014","journal-title":"Diabetes"},{"key":"10.1124\/jpet.124.002347_bib31","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4088\/JCP.12028ah1","article-title":"Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice","volume":"74","author":"Newcomer","year":"2013","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1124\/jpet.124.002347_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","article-title":"Cardiovascular disease in patients with severe mental illness","volume":"18","author":"Nielsen","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1124\/jpet.124.002347_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpsychires.2018.04.019","article-title":"Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis","volume":"102","author":"Oakley","year":"2018","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1124\/jpet.124.002347_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1471-4159.2010.06604.x","article-title":"Basal ganglia pathology in schizophrenia: dopamine connections and anomalies","volume":"113","author":"Perez-Costas","year":"2010","journal-title":"J\u00a0Neurochem"},{"key":"10.1124\/jpet.124.002347_bib35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002347_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res"},{"key":"10.1124\/jpet.124.002347_bib37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","article-title":"A\u00a0possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia","volume":"65","author":"Simpson","year":"2010","journal-title":"Neuron"},{"key":"10.1124\/jpet.124.002347_bib38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.124.002347_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.114.218552","article-title":"In\u00a0vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents","volume":"352","author":"Suzuki","year":"2015","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002347_bib41","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1038\/npp.2016.20","article-title":"TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms","volume":"41","author":"Suzuki","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.124.002347_bib42","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/cns.12798","article-title":"TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia","volume":"24","author":"Suzuki","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1124\/jpet.124.002347_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuroimage.2016.06.047","article-title":"A\u00a0human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor","volume":"141","author":"Takano","year":"2016","journal-title":"Neuroimage"},{"key":"10.1124\/jpet.124.002347_bib44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation","volume":"328","author":"Threlfell","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1124\/jpet.124.002347_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100408","article-title":"Magnetic resonance imaging detects white adipose tissue beiging in mice following PDE10A inhibitor treatment","volume":"64","author":"Tomaszewski","year":"2023","journal-title":"J\u00a0Lipid Res"},{"key":"10.1124\/jpet.124.002347_bib46","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00213-016-4290-1","article-title":"Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity","volume":"233","author":"Vardigan","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.124.002347_bib47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002130000466","article-title":"Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats","volume":"150","author":"Wadenberg","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.124.002347_bib48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","article-title":"Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects","volume":"25","author":"Wadenberg","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.124.002347_bib49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/JCP.0000000000001128","article-title":"Phosphodiesterase 10A inhibitor monotherapy is not an effective treatment of acute schizophrenia","volume":"39","author":"Walling","year":"2019","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1124\/jpet.124.002347_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","article-title":"Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management","volume":"7","author":"Ward","year":"2018","journal-title":"Neurol Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524286961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524286961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.124.002347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:41:33Z","timestamp":1740537693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524286961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022356524286961"],"URL":"https:\/\/doi.org\/10.1124\/jpet.124.002347","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.124.002347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100047"}}